Global Needle Based Biopsy Gun Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Needle Based Biopsy Gun Market Size

• The global needle based biopsy gun market size was valued at USD 612.14 billion in 2025 and is expected to reach USD 1051.77 billion by 2033, at a CAGR of 7.00% during the forecast period
• The market growth is largely fueled by the rising global incidence of cancer and increasing demand for minimally invasive diagnostic procedures, leading to the widespread adoption of needle-based biopsy gun systems in hospitals and diagnostic centers. Advancements in imaging-guided biopsy techniques, including ultrasound and CT-guided procedures, are further enhancing diagnostic accuracy and procedural efficiency, thereby driving market expansion
• Furthermore, growing clinical preference for precise, safe, and rapid tissue sampling solutions, along with the shift toward outpatient and day-care diagnostic procedures, is strengthening the adoption of advanced needle-based biopsy gun technologies. These converging factors are significantly accelerating the uptake of Needle Based Biopsy Gun solutions, thereby boosting the industry's growth

Needle Based Biopsy Gun Market Analysis

• Needle Based Biopsy Gun systems, widely used for image-guided tissue sampling in oncology and pathology, are increasingly vital components of modern diagnostic workflows in hospitals, diagnostic laboratories, and ambulatory surgical centers due to their high precision, minimally invasive nature, and ability to deliver rapid and accurate histopathological results
• The escalating demand for Needle Based Biopsy Gun solutions is primarily fueled by the rising global cancer burden, increasing preference for minimally invasive diagnostic procedures, growing adoption of imaging technologies such as ultrasound, CT, and MRI guidance, and the shift toward early and accurate disease detection, which collectively improve patient outcomes and clinical efficiency
• North America dominated the needle based biopsy gun market with the largest revenue share of 42% in 2025, driven by advanced healthcare infrastructure, high adoption of image-guided biopsy procedures, strong presence of leading medical device manufacturers, and increased cancer screening rates, with the U.S. witnessing significant utilization in hospitals and outpatient diagnostic centers supported by technological advancements in biopsy needle design and guidance systems
• Asia-Pacific is expected to be the fastest growing region in the needle based biopsy gun market during the forecast period, owing to rising healthcare expenditure, expanding access to diagnostic imaging, increasing awareness of early cancer detection, and growing investments in hospital infrastructure across countries such as China, India, and Japan
• The Disposable segment dominated the largest market revenue share of 61.4% in 2025, driven by increasing emphasis on infection control, procedural safety, and reduced risk of cross-contamination in clinical settings

Report Scope and Needle Based Biopsy Gun Market Segmentation

Needle Based Biopsy Gun Market Trends

“Enhanced Precision and Workflow Efficiency Through AI-Assisted Imaging Integration”

• A significant and accelerating trend in the global Needle Based Biopsy Gun market is the integration of artificial intelligence (AI) with imaging modalities such as ultrasound, CT, and MRI to enhance biopsy accuracy, targeting, and procedural efficiency. These advancements are improving lesion detection, reducing sampling errors, and supporting minimally invasive diagnostic workflows
• For instance, AI-assisted biopsy guidance systems used alongside automated core needle biopsy devices from companies such as Hologic and Becton Dickinson are helping clinicians better localize suspicious tissue regions in real time, improving diagnostic yield in breast and soft tissue biopsies
• AI-enabled imaging platforms are increasingly capable of analyzing radiological patterns to suggest optimal needle trajectories, reducing procedure time and improving consistency across operators with varying experience levels
• Integration of digital pathology and AI-based image interpretation is further enabling faster correlation between biopsy samples and imaging findings, supporting earlier and more accurate cancer diagnosis
• The growing use of robotic-assisted and image-guided biopsy systems is also enhancing procedural stability and reducing patient discomfort, particularly in complex anatomical regions
• This trend toward precision-guided, technology-enhanced biopsy procedures is reshaping clinician expectations for diagnostic accuracy and workflow efficiency in oncology and interventional radiology

Needle Based Biopsy Gun Market Dynamics

Driver

“Rising Prevalence of Cancer and Growing Demand for Minimally Invasive Diagnostic Procedures”

• The increasing global burden of cancer, particularly breast, lung, and prostate cancers, is a major driver for the growth of the Needle Based Biopsy Gun market, as early and accurate diagnosis becomes a critical priority in healthcare systems
• For instance, hospitals and diagnostic centers are increasingly adopting vacuum-assisted and core needle biopsy systems from manufacturers such as Hologic and Argon Medical Devices to improve diagnostic precision while minimizing patient trauma compared to traditional surgical biopsy methods
• The shift toward minimally invasive procedures is driven by benefits such as reduced recovery time, lower complication rates, and improved patient comfort, making needle-based biopsy techniques the preferred choice in many clinical settings
• Government-led cancer screening programs and awareness initiatives are further increasing early-stage diagnosis rates, thereby boosting demand for reliable biopsy devices in hospitals and diagnostic laboratories
• In addition, advancements in imaging-guided biopsy technologies are enabling more accurate sampling of small or hard-to-reach lesions, further supporting clinical adoption across oncology applications.

Restraint/Challenge

“High Procedure Cost, Need for Skilled Professionals, and Risk of Clinical Complications”

• The relatively high cost of advanced image-guided and vacuum-assisted biopsy systems remains a key barrier to adoption, particularly in resource-constrained healthcare systems and smaller diagnostic centers
• For instance, in several developing regions, limited access to advanced radiology infrastructure leads healthcare providers to rely on traditional surgical biopsy methods instead of adopting automated needle-based biopsy systems, which require specialized imaging support and trained personnel
• A shortage of skilled interventional radiologists and pathologists trained in image-guided biopsy procedures further restricts the widespread use of advanced biopsy technologies, especially in rural and semi-urban healthcare facilities
• Clinical risks such as bleeding, infection, and sampling errors, although relatively low, still pose concerns among practitioners and patients, particularly in complex or deep-seated lesions
• While technological advancements are improving device accuracy and safety, addressing cost barriers, expanding clinician training programs, and improving healthcare infrastructure will be essential for sustained market growth

Needle Based Biopsy Gun Market Scope

The market is segmented on the basis of product type and application.

• By Product Type

On the basis of product type, the Needle Based Biopsy Gun market is segmented into Disposable and Reusable. The Disposable segment dominated the largest market revenue share of 61.4% in 2025, driven by increasing emphasis on infection control, procedural safety, and reduced risk of cross-contamination in clinical settings. Disposable biopsy guns are widely preferred in hospitals and diagnostic centers due to their single-use nature, ensuring higher sterility and compliance with stringent regulatory guidelines. Rising incidence of cancer globally and increasing number of biopsy procedures are further boosting demand. Hospitals prefer disposable devices due to reduced sterilization burden and improved workflow efficiency. Growing adoption in ambulatory surgical centers also supports segment dominance. Technological advancements have improved precision and ease of use in disposable devices. Increasing healthcare expenditure in emerging economies is further strengthening adoption. Manufacturers are focusing on cost-effective disposable solutions to expand market penetration. Overall, the segment benefits from strong clinical preference and safety advantages.

The Reusable segment is expected to witness the fastest growth rate of 8.9% CAGR from 2026 to 2033, driven by cost-effectiveness over long-term usage and increasing adoption in high-volume healthcare facilities. Reusable biopsy guns are preferred in large hospitals and diagnostic labs where sterilization infrastructure is well established. Growing focus on reducing medical waste and improving sustainability in healthcare is further supporting demand. Technological improvements in device durability and sterilization compatibility are enhancing usability. Reusable systems offer economic benefits for institutions performing a high number of procedures. Increasing investments in hospital infrastructure in developing regions are also contributing to growth. Training programs for safe reuse and sterilization are improving adoption confidence. Manufacturers are introducing advanced reusable devices with enhanced precision and safety features. Rising awareness of sustainable healthcare practices is further driving adoption. These factors collectively make reusable systems the fastest-growing product type segment.

• By Application

On the basis of application, the Needle Based Biopsy Gun market is segmented into Vacuum-Assisted Biopsy Devices (VAB), Core Needle Biopsy Devices (CNB), and Fine Needle Aspiration Biopsy Devices (FNAB). The Core Needle Biopsy Devices (CNB) segment dominated the largest market revenue share of 46.7% in 2025, driven by its high diagnostic accuracy, cost-effectiveness, and widespread clinical use in cancer detection. CNB is extensively used for breast, prostate, and liver biopsies, making it a standard procedure in oncology diagnostics. Increasing global cancer burden is significantly boosting demand for accurate tissue sampling techniques. Hospitals prefer CNB due to its balance between invasiveness and diagnostic yield. Technological advancements in needle design have improved precision and patient comfort. Rising awareness of early cancer detection is further supporting segment growth. Expansion of diagnostic imaging facilities is also contributing to increased adoption. Strong reimbursement frameworks in developed regions enhance usage. CNB remains the most widely adopted biopsy method globally. Overall, it continues to be the backbone of biopsy-based diagnosis.

The Vacuum-Assisted Biopsy Devices (VAB) segment is expected to witness the fastest growth rate of 9.6% CAGR from 2026 to 2033, driven by increasing demand for minimally invasive and highly accurate diagnostic procedures. VAB enables larger and more precise tissue sampling, improving diagnostic accuracy, particularly in breast cancer detection. Rising preference for early-stage cancer diagnosis is significantly boosting adoption. Technological advancements have enhanced imaging-guided biopsy precision. Hospitals and specialized cancer centers are increasingly adopting VAB systems. Growing awareness about advanced diagnostic tools is further supporting growth. Increasing healthcare investments and expansion of oncology infrastructure are driving usage. VAB is also gaining popularity due to reduced need for repeat procedures. Improved patient outcomes and reduced procedural complications are key growth drivers. These factors collectively position VAB as the fastest-growing application segment.

Needle Based Biopsy Gun Market Regional Analysis

• North America dominated the needle based biopsy gun market with the largest revenue share 42% in 2025, driven by advanced healthcare infrastructure, high adoption of image-guided biopsy procedures, strong presence of leading medical device manufacturers, and increased cancer screening rates. The region benefits from widespread availability of minimally invasive diagnostic procedures, with hospitals and outpatient diagnostic centers increasingly integrating technologically advanced biopsy systems for improved accuracy and patient outcomes
• The strong clinical preference for precision-based diagnostics, coupled with continuous innovation in biopsy needle design, automated firing mechanisms, and real-time imaging guidance systems, is further strengthening market growth in North America. Rising awareness regarding early cancer detection and routine screening programs is also contributing significantly to increased procedural volumes
• This widespread adoption is further supported by favorable reimbursement policies, high healthcare expenditure, and robust training of healthcare professionals in image-guided interventional procedures, establishing North America as a key hub for advanced biopsy technologies

U.S. Needle Based Biopsy Gun Market Insight

The U.S. needle based biopsy gun market captured the largest revenue share within North America in 2025, driven by strong adoption of image-guided biopsy techniques and rapid technological advancements in minimally invasive diagnostic tools. Hospitals, cancer specialty centers, and outpatient diagnostic facilities are increasingly utilizing core needle biopsy systems and automated biopsy guns to improve diagnostic accuracy and procedural efficiency. Growing incidence of cancer, along with expanding national screening programs, is significantly boosting procedure volumes across the country. In addition, continuous innovation in needle precision, ergonomic device design, and compatibility with CT, ultrasound, and MRI-guided procedures is further supporting market expansion in the U.S.

Europe Needle Based Biopsy Gun Market Insight

The Europe needle based biopsy gun market is projected to grow at a steady CAGR during the forecast period, driven by increasing cancer prevalence, strong public healthcare systems, and rising emphasis on early and accurate diagnosis. The region is witnessing growing adoption of minimally invasive biopsy procedures across hospitals and diagnostic imaging centers, supported by advancements in interventional radiology. Strict clinical guidelines promoting early cancer detection and the availability of reimbursement support are further encouraging the use of needle-based biopsy systems across major European countries.

U.K. Needle Based Biopsy Gun Market Insight

The U.K. needle based biopsy gun market is expected to grow at a notable CAGR, supported by the National Health Service (NHS) focus on early cancer detection and improved diagnostic efficiency. Increasing adoption of image-guided biopsy procedures in hospitals and specialized diagnostic centers is driving demand for advanced biopsy devices. The rising burden of cancer cases and strong emphasis on reducing diagnostic turnaround times are further accelerating the use of automated and semi-automated biopsy guns in clinical practice.

Germany Needle Based Biopsy Gun Market Insight

The Germany needle based biopsy gun market is expanding steadily due to its advanced healthcare infrastructure, high diagnostic standards, and strong focus on precision medicine. German hospitals and imaging centers are increasingly adopting technologically advanced biopsy systems that offer improved accuracy, reduced tissue trauma, and better procedural control. The integration of biopsy devices with high-resolution imaging systems such as ultrasound and CT guidance is further enhancing diagnostic efficiency across oncology and pathology applications.

Asia-Pacific Needle Based Biopsy Gun Market Insight

The Asia-Pacific needle based biopsy gun market is expected to grow at the fastest CAGR during the forecast period, driven by rising healthcare expenditure, expanding access to diagnostic imaging, increasing awareness of early cancer detection, and growing investments in hospital infrastructure. Countries such as China, India, and Japan are witnessing rapid expansion of diagnostic centers and oncology facilities. Government initiatives aimed at improving cancer screening programs and strengthening healthcare systems are further supporting market growth. Additionally, increasing affordability and availability of advanced biopsy devices are enabling wider adoption across urban and semi-urban healthcare settings.

Japan Needle Based Biopsy Gun Market Insight

The Japan needle based biopsy gun market is gaining momentum due to its advanced healthcare ecosystem, strong focus on early cancer detection, and high adoption of precision diagnostic technologies. Hospitals and specialized cancer centers are increasingly using image-guided biopsy systems integrated with ultrasound and CT imaging. Japan’s aging population is also contributing to higher cancer screening rates, thereby increasing demand for minimally invasive and highly accurate biopsy procedures.

China Needle Based Biopsy Gun Market Insight

The China needle based biopsy gun market accounted for the largest revenue share in Asia-Pacific in 2025, driven by rapid healthcare infrastructure expansion, growing cancer incidence, and strong government focus on early diagnosis programs. The country is witnessing increasing adoption of image-guided biopsy procedures in tertiary hospitals and diagnostic centers. Rising investments in oncology care, combined with the presence of strong domestic medical device manufacturers offering cost-effective solutions, are significantly contributing to market growth across China.

Needle Based Biopsy Gun Market Share

The Needle Based Biopsy Gun industry is primarily led by well-established companies, including:

• BD (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Hologic, Inc. (U.S.)
• Cook Medical (U.S.)
• Argon Medical Devices (U.S.)
• Merit Medical Systems (U.S.)
• Devicor Medical Products (Leica Biosystems) (U.S.)
• INRAD, Inc. (U.S.)
• CareFusion (BD subsidiary) (U.S.)
• Uromed (Germany)
• Biomedical Srl (Italy)
• Laurane Medical (France)
• Sterylab Srl (Italy)
• Stryker Corporation (U.S.)
• Olympus Corporation (Japan)
• Terumo Corporation (Japan)
• Fujifilm Holdings Corporation (Japan)
• Cardinal Health (U.S.)
• Smiths Medical (U.K.)

Latest Developments in Global Needle Based Biopsy Gun Market

• In April 2021, global market research updates highlighted continued expansion of minimally invasive diagnostic tools, with needle-based biopsy guns gaining strong adoption due to rising cancer screening demand and improved accuracy of core needle biopsy systems across hospitals and diagnostic centers globally
• In November 2023, Merit Medical Systems introduced a new lung biopsy system designed for bronchoscopic procedures, expanding the use of needle-based biopsy guns in pulmonary diagnostics and addressing the growing demand for minimally invasive tissue sampling in outpatient settings
• In January 2024, INRAD, Inc. launched a new core needle biopsy device designed for breast and prostate tissue sampling, strengthening its product portfolio in diagnostic oncology and improving precision in tissue extraction procedures used in hospitals and imaging centers
• In March 2024, Cook Medical received FDA clearance for its EchoTip Ultra HD biopsy needle system, featuring enhanced ultrasound visualization and improved ergonomic design to support more accurate tissue sampling and better procedural control during image-guided biopsies
• In June 2024, Becton Dickinson (BD) expanded its biopsy portfolio with MRI-compatible needle-based biopsy technology under its MaxCore product line, enabling clinicians to perform more precise tissue sampling under advanced imaging guidance
• In April 2025, global industry reports indicated strong market expansion in needle-based biopsy gun systems, driven by increasing cancer incidence and growing preference for minimally invasive diagnostic procedures, with companies investing heavily in AI-assisted biopsy guidance and vacuum-assisted biopsy innovations

SKU-68931